Healthpeak Properties Inc (DOC)

Investment Committee Summary

Investment Thesis

At $21.63 (25 August 2026) Healthpeak trades on 12x guided funds from operations, close to its 52-week high, with the distribution rather than growth supplying the return. The market is pricing a stable-rate, slow-growth outpatient and laboratory landlord: mid-single-digit same-store net operating income growth, no re-rating, income as the return. The engine differs on the left tail, not the base. Variance decomposition attributes the great majority of outcome dispersion to the multiple, and the scenario set carries a heavy structural state of rate shock plus laboratory oversupply whose target sits below the 52-week low, alongside a recession state beneath spot. Probability-weighting the paths gives $20.72, with a twelve-month target of $20.68, while the triangulated fair value of $19.99 leaves a gap of -8% to spot, so the shares are fairly valued against that anchor. HOLD follows: the base case is already priced, peer forward multiples are not a usable anchor for a levered REIT carrying net debt of ~$9.5B, and the portfolio's 44% operating margin is a property-level figure rather than a cushion. The single most damaging risk is a sustained cap-rate reset in which funds from operations and the multiple compress together.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($21.63) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural case carries about a fifth of the weight and is mechanically simple. Life-science supply additions keep laboratory vacancy elevated for years, so renewal spreads turn negative just as higher-for-longer rates push cap rates out. Same-store net operating income declines, occupancy slips, and funds from operations per share erode while the applied multiple compresses; both legs of the valuation fail at once, which is why the outcome is not a modest de-rating. With net debt of ~$9.5B, refinancing at higher coupons absorbs a growing share of net operating income, and the distribution leaves little retained cash to deleverage, so a distribution reset becomes plausible rather than remote. The implied structural target sits below the 52-week low, which means the market has not yet priced this path, and nothing in current prints refutes it.

Key Debate

P/E Multiple explains 83% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 53.4× consensus forward EPS, and a peer median 33.8×.

Variant perception: the house view is below-consensus, and the thesis is primarily margin-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Rate Shock / Oversupply / Secular Decline' downside ($10.50) to a 'Bull — Cap-Rate Compression / Re-Rate' bull case ($32.30); the probability-weighted blend (PWEV $20.72) is -4% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.5% of revenue; free cash flow net of SBC is $1.10B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Rate Shock / Oversupply / Secular Decline (20%, $10.50). Structural impairment — rate shock / oversupply / secular decline: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Recession / Occupancy & SS-NOI Decline (17%, $17.10). Cyclical downturn — same-store NOI + occupancy + FFO growth + cap rates / interest rates + dividend weakens for 1–2 years before normalising.
• Base — FFO Growth + Stable Cap Rates (35%, $21.80). Mid-cycle — normalised same-store NOI + occupancy + FFO growth + cap rates / interest rates + dividend; disciplined capital allocation; steady returns.
• Growth — Same-Store NOI + External Growth (20%, $27.50). Upside — NOI growth + cap-rate compression lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Cap-Rate Compression / Re-Rate (8%, $32.30). Upside tail — sustained tight conditions or a structural re-rate on NOI growth + cap-rate compression.

Valuation Triangulation

Two weighted anchors — a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat two numbers as two independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name DCF, sum-of-parts, peer P/E re-rate are not computed, so 60% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

FFO, P/FFO & Distributions

For a REIT, GAAP EPS is meaningless — depreciation is a massive non-cash charge, so REITs are valued on Funds From Operations (FFO ≈ net income + real-estate D&A) and P/FFO, not P/E. Every 'earnings' and 'multiple' figure in this report is therefore on an FFO basis.

The valuation runs on FFO × P/FFO (the standard REIT frame); the cash-flow DCF is omitted (a REIT's development/maintenance capex is funded against the asset base, not free cash). The dividend yield (5.8%) is the income anchor; cap-rate / interest-rate moves and same-store NOI drive the scenarios.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $18.77 and 32% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (83% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $29.40; the peer-median forward P/E is 33.8x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 51% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Peer Quality & Weighting

Quality-weighted forward P/E: 31.7× (simple median 33.8×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $15.12–$22.71, centre $18.50 (-14% vs spot); spot sits at the 86th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Cap-Rate Compression / Re-Rate): $32.30.

Company Overview & Business Model

Healthpeak Properties Inc — REAL ESTATE · REIT - HEALTHCARE FACILITIES. Business description withheld — the description on file does not name this company; reported for correction rather than published under the wrong name.

How it makes money.

Edge. Narrow moat. Authored moat rationale withheld pending re-authoring.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 1240% — cash-backed.

Competitive Moat

Moat sources:

• On-campus / health-system-affiliated medical outpatient buildings with high tenant retention
• Purpose-built life-science lab assets in innovation clusters (specialised, hard to relocate)
• Long-lease credit tenancy tied to hospital systems
• Scale and cost of capital vs sub-scale healthcare landlords

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.42 vs analyst floor +0.00 → delta +0.42 (n=11 mgmt / 6 Q&A; 53rd pctile across the S&P book, z +0.1).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 204 articles): avg ticker sentiment +0.16 (bullish 8% / bearish 1%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-09-30 (~37d) — Merger integration synergy and disposition-programme milestone (authored)
• 2027-02-10 (~170d) — FY2027 FFO and same-store NOI guidance (authored)

Forecast Track Record

• EPS surprise: beat 50% of the last 8 quarters; average surprise +7.2%.
• Prior-forecast backtest (12 snapshots, 2026-06-27→2026-08-20): directional hit-rate 67%; mean predicted -5.0% vs realised -0.6%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

5 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Same-store cash NOI growth (blended portfolio) < 1.5% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Lab segment occupancy < 93% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• FY FFO-as-adjusted per share guidance < $1.80 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Net debt / adjusted EBITDA > 6.0x (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Common dividend declared per share < $0.305 quarterly (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $21.63; 52-week range $15.12–$22.71; engine rating HOLD; house target $20.68 (-4%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $19.99 (-8% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

50.8/100 (confidence band 36.7–64.9), 21st percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 47.9 → 47.9 → 48.2 → 48.1 → 48.1 → 50.5 → 50.9 → 50.9.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $20.72.

Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.33, vs QQQ +0.22 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Covered Call. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• range-bound with rich premium — harvest elevated vol against a holding (a covered call); an iron condor sells both wings if unhedged
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 86th percentile of the cross-section → high vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 54th percentile of its own month-end history (decile 6). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +2.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.

IV term structure (contango, slope +2.9pp): 25-DTE 26% · 116-DTE 29% · 235-DTE 29%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Iron Condor, Cash-Secured Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 25.9% (elevated regime) · expected move ±4.7% (2026-09-18) · put/call OI 0.42 · ATM Δ 0.21 / Θ -0.01 / ν 0.02. Direction: NEUTRAL (implied return -7.6% to triangulated fair value $19.99).

Covered Call (if held) (Income / neutral) — Short 22.5 C · 2026-09-18 · premium $0.12 · yield 0.6% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Elevated implied volatility currently enriches the premium collected. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 20 P / Long 17.5 P · 2026-10-16 · net $0.19 · net entry $19.81 · yield 0.9% · RoR 8.0% · max loss $2.31 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 20 P / Short 25 C · 2027-01-15 · net $-0.45 · floor -8.0% · cap +16.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -4% vs spot
• Monte Carlo median implies -13% vs spot
• Bear case (Structural — Rate Shock / Oversupply / Secular Decline) downside is -51% vs spot
• Net: the valuation anchor itself sits 7.6% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Assumption Register

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

No DCF anchor is meaningful for this asset; the blend leans 62% on probability-weighted scenarios and 37% on the Monte Carlo median — the scenario probabilities are the load-bearing inputs.